BioRestorative Therapies, Inc. (BRTX) vs Nuwellis, Inc. (NUWE)
A side-by-side comparison of BioRestorative Therapies, Inc. and Nuwellis, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BRTX
BioRestorative Therapies, Inc.
$2.21HealthcareDelayed quote: Oct 6, 2026, 12:34 PM EDT
NUWE
Nuwellis, Inc.
$0.71HealthcareDelayed quote: Oct 6, 2026, 12:27 PM EDT
Total return — BRTX vs NUWE
growth of $100 · dividends reinvested · last 10yBRTX -100.0% (-63.1%/yr)NUWE -100.0% (-84.0%/yr)BRTX compounded faster over this window
Log scale — wide-divergence pair
BRTX NUWE
BRTX vs NUWE: by the numbers
- •BRTX is the larger company ($3M vs $3M market cap).
- •Both run net losses; NUWE's is the smaller (-123.38% vs -3089.55% net margin).
- •BRTX grew revenue faster over the past five years (38.99% vs 1.48% CAGR).
Metrics side by side
Valuation
| Metric | BRTX | NUWE |
|---|---|---|
| P/S ratio | 8.53 | 0.29 |
| P/B ratio | 1.01 | N/A |
Profitability
| Metric | BRTX | NUWE |
|---|---|---|
| Gross margin | 92.09% | 69.69% |
| Operating margin | -4350.05% | -140.62% |
| Net margin | -3089.55% | -123.38% |
| ROE | -365.43% | N/A |
| ROIC | -464.86% | -238.32% |
Growth (annualized)
| Metric | BRTX | NUWE |
|---|---|---|
| Revenue CAGR (5Y) | 38.99% | 1.48% |
| Total return CAGR (5Y) | -61.44% | N/A |
Frequently asked
- Which has grown faster, BRTX or NUWE?
- Over the past five years, BRTX grew revenue faster — BRTX at a 38.99% CAGR versus NUWE at 1.48%.
Go deeper
Dig into the metrics
BioRestorative Therapies ROENuwellis ROEBioRestorative Therapies operating marginNuwellis operating marginBioRestorative Therapies revenue growthNuwellis revenue growthBioRestorative Therapies free cash flowNuwellis free cash flow
BioRestorative Therapies & Nuwellis appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.